MedTrace Logo

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2024-04-17

No results posted yet for this study

Summary

This is a Phase Ib/II platform clinical study to evaluate the initial efficacy and safety of different novel immunotherapies in patients with advanced pancreatic cancer.

Conditions

Interventions

DRUG

JS001

240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.

DRUG

JS004

200 mg by IV infusion Q3W, given on cycle day 1.

DRUG

JS007

3mg/kg by IV infusion Q3W, given on cycle day 1.

DRUG

JS015

600mg by IV infusion Q3W, given on cycle day 1.

DRUG

Irinotecan Liposome Injection

60 or 70 mg/m\^2 by IV infusion every 2 weeks (Q2W), given on cycle day 1.

DRUG

5-Fluorouracil (5-FU)

2400mg/m\^2, intravenously, over 46 h on day 1, Q2W.

DRUG

Leucovorin (LV)

400mg/m\^2, intravenously, over 30 min on day 1, Q2W.

DRUG

Nab paclitaxel

125 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

DRUG

Gemcitabine

1000 mg/m\^2 by IV infusion Q3W, given on cycle day 1 and 8.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2026-04-30
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06370754 on ClinicalTrials.gov